Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Deals

AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies

Fineline Cube Jun 25, 2024

AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly...

Company Drug

Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes

Fineline Cube Jun 25, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Drug

Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study

Fineline Cube Jun 25, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...

Company Drug

Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes

Fineline Cube Jun 25, 2024

The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...

Company Drug

Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial

Fineline Cube Jun 25, 2024

Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...

Company Drug

Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval

Fineline Cube Jun 24, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...

Company Deals

ClouDr Secures Exclusive Sub-Licensing Rights for Iloprost Infusion Solution

Fineline Cube Jun 24, 2024

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), operating under the brand name “ClouDr,”...

Legal / IP

Biocytogen Secures US Patent for RenLite Fully Human Common Light Chain Mouse Platform

Fineline Cube Jun 24, 2024

Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for CD47 and CD20 Dual-Targeted BsAb in SLE

Fineline Cube Jun 24, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received clinical trial...

Company Deals

Shanghai Pharmaceuticals’ Subsidiary Shaphar Med Collaborates with Magic Med to Enter Oncology

Fineline Cube Jun 24, 2024

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Go-Ahead for BL-M17D1 Solid Tumor Clinical Study

Fineline Cube Jun 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

StarryGene Initiates Phase I Clinical Trial for XMVA09 Gene Therapy in wAMD

Fineline Cube Jun 24, 2024

StarryGene, a biotech company specializing in gene therapy and based in Hefei, China, has announced...

Company Drug

Gilead’s Lenacapavir Shows 100% Efficacy in Phase III HIV PrEP Study

Fineline Cube Jun 24, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a U.S. biopharmaceutical company, has announced topline results from the...

Policy / Regulatory

Hefei Airport Port Designated as Drug Import Port by Chinese Authorities

Fineline Cube Jun 24, 2024

Hefei Airport Port, located in the city of Hefei, China, has been designated as a...

Company Drug

Zai Lab’s Partner Argenx Receives FDA Approval for CIDP Treatment Vygart Hytrulo

Fineline Cube Jun 24, 2024

Argenx SE (NASDAQ: ARGX), the U.S. partner of China-based biopharmaceutical company Zai Lab Ltd (NASDAQ:...

Company Deals

Inkon Life Technology Partners with United Imaging to Establish Advanced Medical Centers and Digital Platform

Fineline Cube Jun 24, 2024

Inkon Life Technology Co., Ltd. (SHE: 300143), a Shenzhen-based service provider specializing in stereotactic radiotherapy...

Company Deals

METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery

Fineline Cube Jun 24, 2024

METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in...

Company Drug

Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval

Fineline Cube Jun 21, 2024

The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...

Company Deals Medical Device

Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation

Fineline Cube Jun 21, 2024

Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China...

Company Deals

Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial

Fineline Cube Jun 21, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Posts pagination

1 … 380 381 382 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.